Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forbes Medi-Tech seeks approval for cholesterol drug study
The design of the upcoming US phase II trial incorporates the knowledge gathered from both preclinical studies and a European proof of concept trial in humans. The planned
The design of the upcoming US phase II trial incorporates the knowledge gathered from both preclinical studies and a European proof of concept trial in humans. The planned
The study was sponsored by ViaCell and conducted in association with the Toronto General Research Institute at Toronto General Hospital. Four weeks after cell transplantation, engrafted human unrestricted
In work conducted by Dr Michael Czech, professor and chair of molecular medicine at the University of Massachusetts Medical School, and Dr Malcolm Parker of the Imperial College
“Acquiring this license is another milestone in our progress toward beginning our first human clinical trial,” said Martin McGlynn, president and CEO of StemCells. “In addition, the California
Under the terms of the agreement, MicroIslet and The Scripps Research Institute (TSRI) will continue preclinical studies utilizing MicroIslet’s proprietary technologies. MicroIslet believes that the completion of this
Novartis currently holds a 42.2% stake in the US biopharmaceutical company and has submitted a proposal to acquire the approximately 112 million fully diluted shares of Chiron for
Conducted at the University of Texas MD Anderson Cancer Center, this single-site phase II, open label trial will evaluate the efficacy and safety of Fodosine as determined by
As part of the extended collaboration, Aventis has committed a further $18.2 million to ImmunoGen research support over the twelve months beginning September 1, 2006. This funding is
The drug, acquired by Tercica from Genentech, is specifically approved for children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have
The Canadian drug company’s shares fell by almost 50% on the Nasdaq after the announcement of the early closing of the trail. An external monitoring committee also raised